|When Topic is selected you can:
|No Cost site registration required to do any of above.
Among the most active in the ASSETs space, Johnson & Johnson is structured quite differently to most firms in their space, being broadly organized around the areas of Consumer Healthcare
, and Medical Devices and Diagnostics
– areas of interest in each indicated below -. Designated as part of the Family of Companies, some 250 J&J operating entities are located in 57 countries worldwide. With primarily a late-stage development emphasis, these individual operational units can, and do, engage external capabilities specific to their particular market focus and needs. In addition, with major focus of a particular primary areas of emphasis, J&J have skilled scouting personnel with explicit responsibility also to identify and enable collaborations for the relevant operating entities. Importantly, each have the capacity to refer to anywhere in the J&J family structure those sources doing work they judge to be of potential relevance.
In theory – and in practice - quality projects can enter the system at almost any point. Extensively ASSETs involved previously, has been someone with primarily Consumer Healthcare responsibility. With very useful outcomes to those involved, she has made important introductions of SBIR awardees to the relevant people they needed to know wherever in the family structure.
COSAT: Corporate Office of Science & Technology
This time, the Johnson & Johnson presence at ASSETs comes out of COSAT. With overarching responsibility across the full breadth of the firm, within and beyond the Johnson & Johnson operating company structure, COSAT’s role is to:
- Identify and nurture emerging technologies related to health care
- Assess technical risk and business potential of these technologies
- Facilitate the incorporation of these technologies into the Johnson & Johnson Family of Companies
With an early stage opportunities emphasis, COSAT actively seeks out scientific breakthroughs and explore technologies as diverse as molecular diagnostics, cell therapies, nutritionals, medical devices, health care informatics platforms, and bio-artificial organs.